Prophylactic anticoagulation

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Prophylactic anticoagulation is one of 33 small molecule programs targeting Acute Chest Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Chest SyndromeActive, not recruiting

SepsisActive, not recruiting

Acute Chest SyndromePhase 3

Active, not recruiting

SepsisPhase 2

Active, not recruiting

Competition

Competitive Landscape

308 competitors in Sepsis

#DrugCompanyPhaseTrials

Prophylactic anticoagulation

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 2

Corlanor

Amgen

Preclinical

2 3

Simdax

Orion Corporation, Orion Pharma

Preclinical

1 4

Primaxin

Zemplar

Zyvox

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

3 8

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

2 9

Epsom Salt

FFresenius Kabi Oncology Ltd.

Preclinical

1 10

Aquasol a

BBandim Health Project

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Not yet recruiting

Sepsis

NCT06381661

Clinical

Trials by Indication[1]

Sepsis1 trial

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06381661·2,000 enrolled

Acute Chest Syndrome1 trial

Therapeutic Anticoagulation Strategy for Acute Chest Syndrome

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02580773·198 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Prophylactic anticoagulation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prophylactic anticoagulation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prophylactic anticoagulation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Prophylactic anticoagulation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Sepsis1 trial

Acute Chest Syndrome1 trial

References

Drug Info

Quick Facts

Related News